These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 37165196)

  • 41. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
    Hegde S; Krisnawan VE; Herzog BH; Zuo C; Breden MA; Knolhoff BL; Hogg GD; Tang JP; Baer JM; Mpoy C; Lee KB; Alexander KA; Rogers BE; Murphy KM; Hawkins WG; Fields RC; DeSelm CJ; Schwarz JK; DeNardo DG
    Cancer Cell; 2020 Mar; 37(3):289-307.e9. PubMed ID: 32183949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.
    Gautam SK; Kumar S; Dam V; Ghersi D; Jain M; Batra SK
    Semin Immunol; 2020 Feb; 47():101391. PubMed ID: 31952903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
    Keskin DB; Anandappa AJ; Sun J; Tirosh I; Mathewson ND; Li S; Oliveira G; Giobbie-Hurder A; Felt K; Gjini E; Shukla SA; Hu Z; Li L; Le PM; Allesøe RL; Richman AR; Kowalczyk MS; Abdelrahman S; Geduldig JE; Charbonneau S; Pelton K; Iorgulescu JB; Elagina L; Zhang W; Olive O; McCluskey C; Olsen LR; Stevens J; Lane WJ; Salazar AM; Daley H; Wen PY; Chiocca EA; Harden M; Lennon NJ; Gabriel S; Getz G; Lander ES; Regev A; Ritz J; Neuberg D; Rodig SJ; Ligon KL; Suvà ML; Wucherpfennig KW; Hacohen N; Fritsch EF; Livak KJ; Ott PA; Wu CJ; Reardon DA
    Nature; 2019 Jan; 565(7738):234-239. PubMed ID: 30568305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
    PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
    D'Alise AM; Leoni G; Cotugno G; Siani L; Vitale R; Ruzza V; Garzia I; Antonucci L; Micarelli E; Venafra V; Gogov S; Capone A; Runswick S; Martin-Liberal J; Calvo E; Moreno V; Symeonides SN; Scarselli E; Bechter O
    Clin Cancer Res; 2024 Jun; 30(11):2412-2423. PubMed ID: 38506710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
    Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
    Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
    Blass E; Ott PA
    Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.
    Shao J; Liu Q; Shen J; Qian X; Yan J; Zhu Y; Qiu X; Lu C; Cen L; Tian M; Du J; Liu B
    Front Immunol; 2022; 13():799026. PubMed ID: 35273594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer.
    Lin X; Tang S; Guo Y; Tang R; Li Z; Pan X; Chen G; Qiu L; Dong X; Zhang L; Liu X; Cai Z; Xie B
    Cancer Immunol Immunother; 2024 Jan; 73(2):26. PubMed ID: 38280084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.
    Zhang Y; Jiang L; Huang S; Lian C; Liang H; Xing Y; Liu J; Tian X; Liu Z; Wang R; An Y; Lu F; Pan Y; Han W; Li Z; Yin F
    Adv Sci (Weinh); 2024 Jun; 11(24):e2307754. PubMed ID: 38605600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
    Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA
    Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model.
    Shangguan A; Shang N; Figini M; Pan L; Yang J; Ma Q; Hu S; Eresen A; Sun C; Wang B; Velichko Y; Yaghmai V; Zhang Z
    Cytotherapy; 2020 Jan; 22(1):6-15. PubMed ID: 32005355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expanding the Potential of Neoantigen Vaccines: Harnessing Bacille Calmette-Guérin Cell-Wall-Based Nanoscale Adjuvants for Enhanced Cancer Immunotherapy.
    Liu K; Peng J; Guo Y; Li Y; Qi X; Duan D; Li T; Li J; Niu Y; Han G; Zhao Y
    ACS Nano; 2024 May; 18(18):11910-11920. PubMed ID: 38680054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.
    Aurisicchio L; Salvatori E; Lione L; Bandini S; Pallocca M; Maggio R; Fanciulli M; De Nicola F; Goeman F; Ciliberto G; Conforti A; Luberto L; Palombo F
    J Exp Clin Cancer Res; 2019 Feb; 38(1):78. PubMed ID: 30764846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
    Awad MM; Govindan R; Balogh KN; Spigel DR; Garon EB; Bushway ME; Poran A; Sheen JH; Kohler V; Esaulova E; Srouji J; Ramesh S; Vyasamneni R; Karki B; Sciuto TE; Sethi H; Dong JZ; Moles MA; Manson K; Rooney MS; Khondker ZS; DeMario M; Gaynor RB; Srinivasan L
    Cancer Cell; 2022 Sep; 40(9):1010-1026.e11. PubMed ID: 36027916
    [TBL] [Abstract]